|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's range||0.1734 - 0.2491|
|52-week range||0.0600 - 1.5000|
|Beta (5Y monthly)||1.59|
|PE ratio (TTM)||N/A|
|Earnings date||14 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most